MedTrace Logo

Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis

NCT03352206 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20092

Last updated 2020-12-31

No results posted yet for this study

Summary

This study will assess the impact of 2-drug (DA) or 3-drug (IDA) regimens on lymphatic filariasis infection parameters in communities. Parameters measured will include: circulating filarial antigenemia (CFA) assessed with the Filariasis Test Strip (FTS), antifilarial antibodies tested with plasma and microfilaremia (assessed by night blood smears and microscopy).

Conditions

  • Lymphatic Filariases

Interventions

DRUG

2 drug dose - DA

Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine and albendazole (DA)

DRUG

3 drug dose - IDA

Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)

Sponsors & Collaborators

  • Case Western Reserve University

    collaborator OTHER

  • Ministere de la Sante Publique et de la Population, Haiti

    collaborator UNKNOWN

  • Indonesia University

    collaborator OTHER

  • Papua New Guinea Institute for Medical Research

    collaborator UNKNOWN

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Gary Weil, MD · Washington University School of Medicine

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-18
Primary Completion
2019-11-01
Completion
2019-11-01

Countries

  • Fiji
  • Haiti
  • India
  • Indonesia
  • Papua New Guinea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03352206 on ClinicalTrials.gov